Compare Booz Allen Hamilton Holding Corporation (BAH) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Regeneron Pharmaceuticals Inc — how do they compare? Booz Allen Hamilton Holding Corporation trades at $78.55 (market cap $9.37B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.9× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays the higher dividend (3.03%). Which is the better fit depends on your goals.
| BAH | REGN | |
|---|---|---|
Market Cap | $9.37B | $83.19B |
Sector | Industrials | Health |
52-Week High | $111.63 | $812.27 |
52-Week Low | $59.71 | $555.51 |
Enterprise Value | $12.99B | $77.90B |
Dividend Yield | 3.03% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $76.05, up 2.87% with a bullish technical signal and strong earnings beats. Recent quarters show consistent EPS outperformance, with Q2 2026 actual EPS of $1.81 beating the $1.49 estimate. The stock benefits from a discounted valuation with a P/E of 11.94 and robust cash flow growth, though revenue declined 4.2% year-over-year in Q1 2027. National security demand remains a key driver, offset by civil segment weakness.
Outlook is cautiously positive with a consensus price target of $84.67, implying 11% upside. Strengths include high ROE of 68.11% and margin expansion, but risks involve elevated debt levels and revenue volatility. Investors should weigh valuation appeal against execution risks in government contracting.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
